Semaglutide Market Hits Speed Bump with ₹100 Crore Excess Stock
The meteoric rise of the weight-loss and semaglutide therapy market in India has encountered an unexpected setback. After a massive surge following patent expiries, the sector is now grappling with a significant inventory overhang that threatens to disrupt the supply chain.
The Inventory Crisis: A ₹100 Crore Overhang
The much-hyped obesity therapy market, valued at approximately ₹2,000 crore, has seen a sharp deceleration in momentum. Industry sources indicate that stockists and wholesalers are currently sitting on an excess inventory valued at nearly ₹100 crore.
According to Rajiv Singhal, General Secretary of the All India Organisation of Chemists and Druggists (AIOCD), the trade channel is holding 50–60 days of semaglutide stock. This is significantly higher than the industry standard of 30–45 days. As a result, channel partners have implemented a freeze on fresh procurement from pharmaceutical companies, waiting for existing stocks to liquidate before placing new orders.
From Rapid Growth to Sluggish Sales
The current slowdown follows a period of explosive growth. In April, the market witnessed a massive surge, with value growth jumping 50% month-on-month and volumes increasing by 88%. This spike was largely driven by the influx of cheaper generic semaglutide brands from major pharmaceutical players like Sun Pharma, Dr. Reddy’s, and Torrent following the drug's patent expiry on March 20.
However, the May data tells a different story. Market research firm Pharmarack reports that month-on-month value growth slowed to just 6%, while unit growth cooled to 12%. This sudden moderation has left the distribution network struggling to balance the supply of new generics against the slowing demand.
Regulatory Hurdles and Market Competitors
Industry executives suggest that the cooling demand might not be purely organic. Recent government advisories and prescribing restrictions regarding GLP-1 therapies have likely impacted uptake. Specifically, new guidelines announced in April mandate that these medicines be prescribed only by qualified specialists, which may have created friction in the prescribing patterns of general practitioners.
Despite the semaglutide volatility, the broader GLP-1 receptor agonist market shows pockets of strength. Mounjaro (tirzepatide), marketed by Eli Lilly, remains the dominant player in the segment. In May, Mounjaro's sales grew by 12%, reaching ₹136 crore. This performance contributed to the overall growth of India's ₹2.5 lakh crore organized pharma retail market, which expanded by nearly 11% during the month, primarily driven by chronic therapies.
Key Takeaways
- Significant Inventory Glut: Stockists are holding 50–60 days of semaglutide inventory, creating a ₹100 crore overhang in the trade channel.
- Decelerating Growth: After a 50% value surge in April, May saw growth plummet to just 6%, leading to a pause in fresh procurement.
- Regulatory Impact: New guidelines requiring specialists to prescribe GLP-1 therapies may be contributing to the sudden moderation in sales.